# A Dose-Ranging Study of IV BNZ-1 in LGL Leukemia or Refractory CTCL

> **NCT03239392** · PHASE1,PHASE2 · COMPLETED · sponsor: **Bioniz Therapeutics** · enrollment: 50 (actual)

## Conditions studied

- LGL Leukemia
- CTCL

## Interventions

- **DRUG:** BNZ132-1-40

## Key facts

- **NCT ID:** NCT03239392
- **Lead sponsor:** Bioniz Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-04-01
- **Primary completion:** 2020-06-30
- **Final completion:** 2020-06-30
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2021-05-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03239392

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03239392, "A Dose-Ranging Study of IV BNZ-1 in LGL Leukemia or Refractory CTCL". Retrieved via AI Analytics 2026-05-21 from https://api.ai-analytics.org/clinical/NCT03239392. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*